Rhenman & Partners Asset Management Ab Esperion Therapeutics, Inc. Transaction History

Rhenman & Partners Asset Management Ab

$1.2 Billion
Q3 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 1,975,000 shares of ESPR stock, worth $4.76 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares

1,975,000

Previous 1,975,000 -0.0%

Holding current value

$4.76 Million

Previous $4.38 Million 25.68%

% of portfolio

0.27%

Previous 0.43%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.84 - $3.24 $3.63 Million - $6.4 Million	1,975,000 New	1,975,000 $4.38 Million
Q2 2022 Aug 12, 2022	SELL	$4.77 - $6.67 $389,146 - $544,151	-81,582 Reduced 8.31%	900,000 $5.72 Million
Q1 2022 May 13, 2022	SELL	$3.34 - $5.56 $61,516 - $102,404	-18,418 Reduced 1.84%	981,582 $4.56 Million
Q4 2021 Feb 11, 2022	BUY	$4.81 - $11.92 $1.82 Million - $4.5 Million	377,733 Added 60.7%	1,000,000 $4.96 Million
Q3 2021 Nov 12, 2021	BUY	$11.34 - $21.37 $567,000 - $1.07 Million	50,000 Added 8.74%	622,267 $7.5 Million
Q2 2021 Aug 13, 2021	SELL	$19.4 - $28.71 $387,185 - $572,994	-19,958 Reduced 3.37%	572,267 $12.1 Million
Q4 2020 Jan 19, 2021	BUY	$24.2 - $35.76 $3.32 Million - $4.91 Million	137,225 Added 30.16%	592,225 $15.4 Million
Q3 2020 Oct 13, 2020	BUY	$31.18 - $52.71 $935,400 - $1.58 Million	30,000 Added 7.06%	455,000 $16.9 Million
Q2 2020 Jul 16, 2020	SELL	$30.04 - $51.31 $5.04 Million - $8.61 Million	-167,798 Reduced 28.31%	425,000 $21.8 Million
Q1 2020 Apr 16, 2020	SELL	$27.44 - $73.84 $1.84 Million - $4.96 Million	-67,202 Reduced 10.18%	592,798 $18.7 Million
Q4 2019 Jan 17, 2020	BUY	$35.4 - $59.82 $146,768 - $248,013	4,146 Added 0.63%	660,000 $39.4 Million
Q3 2019 Oct 16, 2019	BUY	$34.47 - $47.53 $8.4 Million - $11.6 Million	243,761 Added 59.15%	655,854 $24 Million
Q2 2019 Jul 22, 2019	SELL	$40.1 - $52.33 $2.71 Million - $3.54 Million	-67,674 Reduced 14.11%	412,093 $19.2 Million
Q1 2019 Apr 11, 2019	BUY	$40.11 - $53.57 $5.05 Million - $6.74 Million	125,806 Added 35.54%	479,767 $19.3 Million
Q3 2018 Oct 03, 2018	SELL	$40.74 - $51.41 $2.13 Million - $2.69 Million	-52,400 Reduced 12.89%	353,961 $15.7 Million
Q2 2018 Jul 20, 2018	BUY	$36.2 - $76.4 $5.86 Million - $12.4 Million	161,821 Added 66.17%	406,361 $15.9 Million
Q1 2018 Apr 11, 2018	SELL	$65.94 - $80.76 $9.37 Million - $11.5 Million	-142,086 Reduced 36.75%	244,540 $17.7 Million
Q4 2017 Jan 19, 2018	BUY	$43.47 - $67.43 $3.25 Million - $5.05 Million	74,823 Added 24.0%	386,626 $25.5 Million
Q3 2017 Oct 13, 2017	BUY	$43.8 - $52.77 $13.7 Million - $16.5 Million	311,803	311,803 $15.6 Million

Others Institutions Holding ESPR

# of Institutions

208

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Esperion Therapeutics, Inc. Transaction History